A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors
Clinical trial NCT06934616 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06934616
- Sponsor
- Genor Biopharma Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-24
- Primary completion
- 2027-03-01
- Enrollment
- 330
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.